BriaPro subsidiary reports $740K loss; going concern doubt flagged by auditor

BriaCell Therapeutics Corp.

BriaPro net loss $740,216 for year ended July 31, 2025, accumulated deficit $1,180,425.
Auditor's report includes material uncertainty about BriaPro's ability to continue as a going concern.
BriaPro has $1 cash, $1.15M current liabilities, and total assets of $184,526 primarily intangible assets.
Subsidiary wholly dependent on BriaCell for financing; no commercial operations yet.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.